{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:57:20Z","timestamp":1792637840410,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ahj.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T03:12:01Z","timestamp":1660878721000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-1081","authenticated-orcid":false,"given":"J","family":"Kranendonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LH","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RJ. van der","family":"Vijver-Coppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Coenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Adang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CJ","family":"Zeebregts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VHM","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MMPJ","family":"Reijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kramers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MC","family":"Warl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2022.08.001_bib0001","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2018.05.033","article-title":"Update on peripheral artery disease: epidemiology and evidence-based facts","volume":"275","author":"Shu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2022.08.001_bib0002","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for reports dealing with lower extremity ischemia: revised version","volume":"26","author":"Rutherford","year":"1997","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2022.08.001_bib0003","unstructured":"Richtlijnendatabase. Richtlijn perifeer arterieel vaatlijden 2016"},{"key":"10.1016\/j.ahj.2022.08.001_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejvs.2017.07.018","article-title":"Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"55","author":"Aboyans","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2022.08.001_bib0005","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jcph.293","article-title":"Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers","volume":"54","author":"Horenstein","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2022.08.001_bib0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2011.127","article-title":"Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects","volume":"90","author":"Simon","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2022.08.001_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","article-title":"genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis","volume":"135","author":"Pan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.08.001_bib0008","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","article-title":"CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis","volume":"7","author":"Sorich","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11596-015-1404-7","article-title":"CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis","volume":"35","author":"Niu","year":"2015","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.ahj.2022.08.001_bib0010","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.08.001_bib0011","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FJC.0000000000000337","article-title":"Clinical Value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population","volume":"67","author":"Shen","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2022.08.001_bib0012","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.ijcard.2013.06.014","article-title":"Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial","volume":"168","author":"Xie","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2022.08.001_bib0013","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2022.08.001_bib0014","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A Genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.08.001_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18433\/jpps32140","article-title":"Genotype-guided antiplatelet therapy versus standard therapy for patients with coronary artery disease: an updated systematic review and meta-analysis","volume":"25","author":"Tang","year":"2022","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.ahj.2022.08.001_bib0016","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0017","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y(12) inhibitor therapy: a meta-analysis","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2022.08.001_bib0018","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ccd.28075","article-title":"Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: a network meta-analysis of randomized clinical trials","volume":"94","author":"Kheiri","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2022.08.001_bib0019","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2022.08.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2022.08.001_bib0021","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/SLA.0000000000002558","article-title":"Carotid artery reactivity predicts events in peripheral arterial disease patients","volume":"269","author":"van Mil","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.ahj.2022.08.001_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09537104.2017.1413178","article-title":"CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis","volume":"30","author":"Xi","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.ahj.2022.08.001_bib0023","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.thromres.2014.12.007","article-title":"Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis","volume":"135","author":"Zhang","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2022.08.001_bib0024","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/1354750X.2019.1634764","article-title":"Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis","volume":"24","author":"Zheng","year":"2019","journal-title":"Biomarkers"},{"issue":"7","key":"10.1016\/j.ahj.2022.08.001_bib0025","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ccd.27949","article-title":"CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: a meta-analysis of randomized clinical trials","volume":"93","author":"Kheiri","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2022.08.001_bib0026","unstructured":"Nederland Z. Budget impact analyse van rivaroxaban (Xarelto\u00ae) voor de preventie van atherotrombotische complicaties bij volwassen pati\u00ebnten met coronaire hartziekte (CHZ) of symptomatische perifeer arterieel vaatlijden (PAV) met een hoog risico op ischemische voorvallen 2019."},{"key":"10.1016\/j.ahj.2022.08.001_bib0027","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0091270009355161","article-title":"Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans","volume":"50","author":"Man","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ahj.2022.08.001_bib0028","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0029","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","article-title":"Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin","volume":"4","author":"Jeong","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2022.08.001_bib0030","unstructured":"Nederland Z. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016."},{"issue":"1","key":"10.1016\/j.ahj.2022.08.001_bib0031","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus Clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.08.001_bib0032","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ahj.2020.07.017","article-title":"CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: insights from the EUCLID Trial","volume":"229","author":"Gutierrez","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2022.08.001_bib0033","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejvs.2019.02.011","article-title":"CYP2C19 polymorphism is associated with amputation rates in patients taking clopidogrel after endovascular intervention for critical limb ischaemia","volume":"58","author":"Lee","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2022.08.001_bib0034","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jvs.2014.03.293","article-title":"Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease","volume":"60","author":"Guo","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2022.08.001_bib0035","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0036","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0037","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0038","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2022.08.001_bib0039","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.08.001_bib0041","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2022.08.001_bib0042","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehs059","article-title":"The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study","volume":"33","author":"Bhatt","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.08.001_bib0043","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.08.001_bib0044","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.08.001_bib0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Collaboration","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2022.08.001_bib0046","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcin.2008.09.004","article-title":"Clopidogrel 150 mg\/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study","volume":"1","author":"Aleil","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2022.08.001_bib0047","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","article-title":"A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days","volume":"28","author":"von Beckerath","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.08.001_bib0048","first-page":"489","article-title":"The diagnostic utility of the point-of-care CYP2C19 genotyping assay in patients with acute coronary syndrome dosing clopidogrel: comparison with platelet function test and SNP genotyping","volume":"46","author":"Choi","year":"2016","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.ahj.2022.08.001_bib0049","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs","author":"Brouwer","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ahj.2022.08.001_bib0050","unstructured":"(NECF) NEvCF. Regionale richtlijn Directe Orale Anticoagulantia (DOAC) Non- VKA Orale Anticoagulantia (DOAC). 2020."}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322001636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322001636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T13:02:51Z","timestamp":1672059771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870322001636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":50,"alternative-id":["S0002870322001636"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2022.08.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}